The IL1B Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human oral squamous cell carcinoma line CAL-27, designed to disrupt the IL1B gene. This product provides a loss-of-function model for investigating IL-1??-dependent signaling in a malignant epithelial context. The polyclonal format represents a heterogeneous knockout pool, suitable for functional studies without clonal selection biases. By eliminating IL-1?? secretion, these cells enable dissection of autocrine and paracrine inflammatory loops that are often active in tumor microenvironments.
CAL-27 is an adherent epithelial cell line established from a human tongue squamous cell carcinoma. It serves as a well-characterized model for oral cancer biology, including tumor proliferation, invasion, and interaction with the inflammatory milieu. The cells retain key features of oral squamous cell carcinoma and are commonly employed in studies of cytokine-mediated tumor progression. Their epithelial origin and malignant phenotype make them particularly relevant for examining how IL-1?? influences cancer cell behavior and crosstalk with stromal and immune components.
IL1B encodes the pro-inflammatory cytokine interleukin-1??, a potent mediator of innate and adaptive immunity. Upon stimulation by upstream regulators such as TNF, Toll-like receptor ligands (e.g., LPS), or the NLRP3 inflammasome activator ATP, IL-1?? is processed and secreted. It binds to its primary receptor IL1R1, which complexes with the accessory protein IL1RAP, recruiting the adaptor MYD88 and kinases IRAK4 and IRAK1. This triggers a signaling cascade involving TRAF6, TAK1, the IKK complex, and mitogen-activated protein kinases (p38, JNK), culminating in activation of transcription factors NF-??B and AP-1. Consequently, IL-1?? drives expression of multiple downstream targets, including cytokines IL6 and IL8 (CXCL8), cyclooxygenase-2 (PTGS2), matrix metalloproteinases (MMPs), and adhesion molecules such as ICAM1. The system is tightly regulated by the endogenous antagonist IL1RN (IL-1Ra) and decoy receptor IL1R2. In the knockout cells, disruption of IL1B abolishes this signaling axis, impairing the NF-??B and MAPK pathways and reducing the transcriptional induction of inflammatory mediators.
In the context of oral squamous cell carcinoma, IL-1?? is often overexpressed and contributes to a pro-tumorigenic inflammatory environment. It can promote cancer cell proliferation, migration, invasion, and epithelial-mesenchymal transition, partly through MMP induction and NF-??B-driven survival signals. The CAL-27 polyclonal knockout model allows researchers to assess the contribution of endogenously produced IL-1?? to these malignant phenotypes. Furthermore, co-culture experiments with immune cells can reveal how loss of tumor-derived IL-1?? alters communication with the microenvironment, potentially affecting processes such as immune evasion and angiogenesis.
Typical research applications include Western blotting and phospho-specific analysis to evaluate NF-??B and MAPK activation status, ELISA or RT-qPCR quantification of downstream cytokines like IL-6 and IL-8, and cell-based assays for proliferation (MTT), migration, and invasion. These polyclonal cells are also valuable for screening anti-inflammatory compounds, studying NLRP3 inflammasome function, and performing RNA-seq to map IL-1??-dependent transcriptomes. The model supports studies of cytokine networks in squamous cell carcinoma and beyond, bridging inflammatory signaling and cancer biology. For more information, please contact Ascent Research.
